Cardiovascular

The Blue Cross Blue Shield of Michigan Cardiovascular Consortium, or BMC2, is a prospective, multicenter, collaborative effort to assess and improve quality of care and outcomes for patients with coronary disease, with a focus on the following three areas:

  • Percutaneous Coronary Intervention – commonly known as angioplasty.
  • Vascular Surgery – patients with peripheral vascular disease who are undergoing open abdominal aneurysm repair, endovascular abdominal aneurysm repair and open bypass procedures of upper and lower extremities. The project also collects data on carotid artery stenting and carotid endarterectomy.
  • TAVR (Transcatheter Aortic Valve Replacement) – percutaneous valve replacement procedures

For more information, go to bmc2.org.

Results

The Blue Cross Blue Shield of Michigan Cardiovascular Consortium-Percutaneous Coronary Intervention (BMC2-PCI) was the first Collaborative Quality Initiative.  Results to date include:

PCI:

  • 20% reduction in risk adjusted mortality (2010 – 2017)
  • 37% reduction in risk adjusted acute kidney injury (2010 – 2017)
  • 54% reduction in transfusion (2010 – 2017)
  • 37% reduction in contrast volume >= 3x eGFR (2010-2017)
  • 24% reduction in vascular access complications (2010 – 2017)

Vascular Surgery:

  • 20% reduction in surgical site infection (2014 – 2017)
  • 41% increase in Chlorhexidine and alcohol skin prep (2012 – 2017)
  • 23% increase in Statins prescribed at discharge (2012 – 2017)
  • 62% decrease in transfusions when HgB>8 (2014 – 2017)
  • 127% increase in pre-procedure hydration for high risk EVAR (2012- 2017)

TAVR:

  • 23% decrease in Contrast Induced Nephropathy (Q3 2017 – Q2 2018)
  • 36% decrease in vascular access complications (2015 – Q2 2018)
  • 46% decrease in transfusion (2015 – 2018)
  • 10% increase in the use of echo pre and post procedurally (2015 – 2017)